catalinagarcia

Vascular endothelial growth factor receptor type2 (VEGFR2) is a receptor tyrosine kinase (RTK) overexpressed in a variety of cancer cells especially in metastatic cancer cells such as melanoma and renal cancer. It belongs to the VEGFR superfamily and plays important roles in tumor cell proliferation, survival, invasion and tumor angiogenesis owing to high dependency of tumor cells on the tumor vasculature. Learn more: anti-VEGFR2 CAR-T in vivo assay

Architects of Cells and Key Players in Disease

Within the intricate microcosm of human cells, comparable to a sophisticated symphony orchestra, ribosomes assume the role of conductors, finely coordinating the synthesis of proteins—the fundamental building blocks of life. Yet, disturbances in ribosomal function intricately connect with cellular dysfunction, playing a significant role in the initiation and progression of diverse diseases. Cellular ribosomal anomalies…

Read More

Enhancing Drug Development With Half-life Extension Strategies

The field of biopharmaceuticals is playing an increasingly pivotal role in medical treatment but is encountering several challenges. One pressing issue is the short half-life of many biopharmaceutical products, which leads to rapid degradation and clearance from the patient’s body, necessitating frequent dosing. In this article, we explore how half-life extension strategies in drug development…

Read More

A New Approach to mRNA Delivery

Lentivirus, adenovirus, adeno-associated virus (AAV), and lipid nanoparticle (LNP) are currently the main delivery vectors used for human gene therapy, but some of these delivery vectors can randomly integrate into the genome, some are ineffective, and some can trigger unintended immune responses. The entire biomedical community is striving to develop new and more powerful molecular therapies,…

Read More

An AIDS drug may treat neurodegenerative disease

At first glance, there appears to be no connection between the AIDS drug CCR inhibitor Maraviroc and neurodegenerative diseases. Maraviroc, a CCR5 inhibitor already approved in 2007, mechanistically binds to the CCR5 molecule and blocks the association of the HIV protein gp120 with the CCR5 receptor, resulting in the inability of HIV to enter the body. In…

Read More